{"product_id":"bax-inhibitor-peptide-v5-p1079","title":"Bax inhibitor peptide V5","description":"\u003ch2\u003eAbout the Target\u003c\/h2\u003e\u003cp\u003eBax inhibitor peptide V5 (BIP-V5 , BAX Inhibiting Peptide V5) is a cell-permeable pentapeptide that blocks the ku70 binding domain and prevents Bax conformational change and mitochondrial translocation. The mapped biological anchor for this entry is BCL2-associated X protein (BAX), although the description suggests that interpretation should remain at fragment, family, or pathway level. The mapped biology is best interpreted at pathway or interactome level, where the peptide is used to bias a response without assuming that every downstream change reflects exclusive engagement of one molecular species. This biology is frequently examined in cell-stress models, where investigators relate pathway changes to mitochondrial stress, survival signaling, and caspase-linked outcomes. For experimental design, the entry is most informative in studies that combine pathway-proximal and phenotype-level readouts.\u003c\/p\u003e\u003ch2\u003eResearch Context\u003c\/h2\u003e\u003cp\u003eBecause it blocks a specific interaction within an apoptotic pathway, interpretation often benefits from pairing it with mitochondrial and cell-death readouts rather than relying on a single endpoint. In practice, dose-response design, timing, and matched control conditions are important for separating direct target engagement from delayed compensatory responses. Because the enrichment is not fully single-target, conclusions are usually strongest when they are framed around the intended biological process and confirmed with orthogonal markers.\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003epair treatment with orthogonal pathway biomarkers whenever direct target engagement cannot be assumed\u003c\/li\u003e\n\u003cli\u003euse dose-response and time-course designs to connect early pathway shifts with later phenotypic outcomes\u003c\/li\u003e\n\u003cli\u003eframe conclusions at network level when more than one molecular node may contribute to the effect\u003c\/li\u003e\n\u003c\/ul\u003e\u003cp\u003eExperimental interpretation should therefore connect early pathway changes with later phenotypic outputs, rather than relying on a single endpoint in isolation.\u003c\/p\u003e\u003ch2\u003eFormat Considerations\u003c\/h2\u003e\u003cp\u003eUsing the regular format helps keep comparative experiments aligned, especially when the same signaling question is being tested across multiple models or readout platforms. In comparative workflows, consistency of preparation, exposure window, and matched controls is often as important as the nominal treatment itself. This is particularly helpful for comparative experiments, benchmark studies, and orthogonal validation in which small differences in formulation or handling can complicate interpretation. For peptide-centered workflows, conclusions are usually strongest when biological readouts are paired with consistent preparation and appropriately matched reference conditions.\u003c\/p\u003e","brand":"Selleck Chemicals","offers":[{"title":"1 mg","offer_id":57636815864153,"sku":"P1079-1MG","price":122.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0923\/1011\/0553\/files\/p1079-Bax-inhibitor-peptide-V5-chemical-structure.png?v=1774212241","url":"https:\/\/absource-diagnostics.myshopify.com\/products\/bax-inhibitor-peptide-v5-p1079","provider":"Absource Diagnostics","version":"1.0","type":"link"}